Cardiomyocyte Ion Channel Modulation for Engraftment Arrhythmia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cardiomyocyte replacement therapy for cardiovascular disease is hindered by transitory arrhythmias caused by human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) after transplantation, which can be fatal and persist for several weeks, necessitating compositions and methods to prevent or treat these electrical disturbances.
Innovation Solution
Modulating the activity of specific ion channels, specifically inhibiting HCN4, CACNA1H, and SLC8A1, while stimulating KCNJ2, in in vitro-differentiated cardiomyocytes to reduce or eliminate engraftment arrhythmias by genetic manipulation or drug intervention, thereby promoting their integration into cardiac tissue without disrupting normal electrophysiological function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human pluripotent stem cell-derived cardiomyocytes are used for cardiac regeneration, then heart function can be restored after damage, but transitory arrhythmias occur after transplantation
Solution Approach 1:
The patent modifies electrophysiological parameters of cardiomyocytes by manipulating ion channel expression (HCN4, CACNA1H, SLC8A1, KCNJ2) to change their electrical properties. This resolves the contradiction by adjusting the electrical characteristics of transplanted cells to match host tissue, thereby maintaining heart function restoration while preventing arrhythmias.
Solution Approach 2:
The patent introduces ion channel modulators as intermediary substances that mediate between the transplanted cardiomyocytes and the host cardiac tissue. These modulators (pharmacological agents or genetic tools) facilitate electrical compatibility and integration, allowing the transplanted cells to function without causing harmful arrhythmias.
2Object-affected harmful factors
If ion channel manipulation is applied to reduce arrhythmias, then engraftment arrhythmias are reduced or eliminated, but the complexity of cell modification increases
Solution Approach 1:
The patent segments the ion channel manipulation into discrete, targetable components (HCN4, CACNA1H, SLC8A1, KCNJ2). By addressing each ion channel separately through specific pharmacological agents or genetic tools, the complexity is managed through systematic modification rather than attempting to alter all cellular properties simultaneously.
Solution Approach 2:
The patent applies preliminary ion channel manipulation during the in vitro differentiation or preparation phase of cardiomyocytes before transplantation. By pre-modifying the electrophysiological properties of cells in the laboratory, the complexity of post-transplant arrhythmia management is avoided, and cells are prepared in advance to integrate smoothly with host tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach significantly reduces or eliminates engraftment arrhythmias in cardiomyocytes, enhancing their integration with cardiac tissue and improving patient outcomes by modulating the ion channel activity, thereby reducing the risk of fatal arrhythmias.
Implementation Method 1
modification of the activity of a set of ion channels that modulate electrophysiological function in graft cardiomyocytes
Implementation Method 2
inhibition or knock-out of the activity or expression of HCN4, CACNA1H and SLC8A1
Implementation Method 3
activation or overexpression of the KCNJ2 (Kir2.1) polypeptide sharply reduces or eliminates such disturbances
Data Source
AI summary
Described herein are compositions and methods related to the treatment of a cardiovascular disease or disorder. Also described herein are cells, stem cells (including embryonic and pluripotent stem cells), and in vitro-differentiated human cardiomyocytes in which HCN4 (HCN4), Cav3.2 (CACNA1H) and NCX1 (SLC8A1) activities are at least partially inhibited, and Kir2.1 (KCNJ2) activity is at least partially stimulated in such cells. Also described herein are formulations for the delivery of such cells and methods of transplanting cardiomyocytes, e.g., for the treatment or prevention of a disease or disorder.